Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry
In a German real-world setting, patients initiating OCR achieved higher rates of persistence over 2 years compared with those on other DMTs. High persistence was associated with lower risk of clinical disease activity, disease progression, and sick leave.
Authors
- Yanic Heer
- Evan Davies
- Seya Colloud
- Petra Dirks
- Diana Sun (ORCID: https://orcid.org/0000-0003-0746-0467)
- Qing Wang (ORCID: https://orcid.org/0000-0001-7698-1317)
- Stefan Braune (ORCID: https://orcid.org/0000-0002-0541-8196)
- M. Zürcher
- Arnfin Bergmann
Institutions
- Roche (Switzerland) (CH)
- Union Bank of Switzerland (CH)
- Metrogiprotrans (Russia) (RU)
- Klinik Donaustauf (DE)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1007/s40120-025-00762-6
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- F. Hoffmann-La Roche